Celldex Therapeutics, Inc. (CLDX) stock
CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$28.04−0.55 (-1.92%)
Close on Nov 17, 2026Market cap $2.20BP/E –Yield –
Celldex Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Celldex Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $158.00K, down 97.3% year over year. For fiscal 2025 it was $1.55M, down 78.0% from the year before. Over ten years it grew -11.9% a year on average. The highest annual figure on record is $46.79M in fiscal 2010.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.55M | -78.0% |
| FY2024 | Dec 31, 2024 | $7.02M | +2.0% |
| FY2023 | Dec 31, 2023 | $6.88M | +192.0% |
| FY2022 | Dec 31, 2022 | $2.36M | -49.3% |
| FY2021 | Dec 31, 2021 | $4.65M | -37.3% |
| FY2020 | Dec 31, 2020 | $7.42M | +107.6% |
| FY2019 | Dec 31, 2019 | $3.57M | -62.5% |
| FY2018 | Dec 31, 2018 | $9.54M | -25.2% |
| FY2017 | Dec 31, 2017 | $12.74M | +87.8% |
| FY2016 | Dec 31, 2016 | $6.79M | +23.8% |
| FY2015 | Dec 31, 2015 | $5.48M | +52.8% |
| FY2014 | Dec 31, 2014 | $3.59M | -12.8% |
| FY2013 | Dec 31, 2013 | $4.11M | -63.3% |
| FY2012 | Dec 31, 2012 | $11.20M | +20.9% |
| FY2011 | Dec 31, 2011 | $9.27M | -80.2% |
| FY2010 | Dec 31, 2010 | $46.79M | +208.3% |
| FY2009 | Dec 31, 2009 | $15.18M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $22.00K | -97.0% |
| Q1 FY2026 | Mar 31, 2026 | $15.00K | -97.8% |
| Q4 FY2025 | Dec 31, 2025 | $121.00K | -89.7% |
| Q3 FY2025 | Sep 30, 2025 | $0 | -100.0% |
| Q2 FY2025 | Jun 30, 2025 | $730.00K | -70.8% |
| Q1 FY2025 | Mar 31, 2025 | $695.00K | +345.5% |
| Q4 FY2024 | Dec 31, 2024 | $1.18M | -71.6% |
| Q3 FY2024 | Sep 30, 2024 | $3.19M | +110.3% |
| Q2 FY2024 | Jun 30, 2024 | $2.50M | +832.1% |
| Q1 FY2024 | Mar 31, 2024 | $156.00K | -83.9% |
| Q4 FY2023 | Dec 31, 2023 | $4.13M | +156.1% |
| Q3 FY2023 | Sep 30, 2023 | $1.52M | +272.7% |
| Q2 FY2023 | Jun 30, 2023 | $268.00K | +64.4% |
| Q1 FY2023 | Mar 31, 2023 | $967.00K | +455.7% |
| Q4 FY2022 | Dec 31, 2022 | $1.61M | +382.9% |
| Q3 FY2022 | Sep 30, 2022 | $407.00K | +166.0% |
| Q2 FY2022 | Jun 30, 2022 | $163.00K | -95.3% |
| Q1 FY2022 | Mar 31, 2022 | $174.00K | -74.6% |
| Q4 FY2021 | Dec 31, 2021 | $334.00K | -91.2% |
| Q3 FY2021 | Sep 30, 2021 | $153.00K | -77.1% |
| Q2 FY2021 | Jun 30, 2021 | $3.48M | +1374.6% |
| Q1 FY2021 | Mar 31, 2021 | $685.00K | -74.9% |
| Q4 FY2020 | Dec 31, 2020 | $3.79M | +326.8% |
| Q3 FY2020 | Sep 30, 2020 | $668.00K | +22.3% |
| Q2 FY2020 | Jun 30, 2020 | $236.00K | -67.0% |
| Q1 FY2020 | Mar 31, 2020 | $2.73M | +91.4% |
| Q4 FY2019 | Dec 31, 2019 | $887.00K | -49.7% |
| Q3 FY2019 | Sep 30, 2019 | $546.00K | -42.0% |
| Q2 FY2019 | Jun 30, 2019 | $715.00K | -74.1% |
| Q1 FY2019 | Mar 31, 2019 | $1.43M | -65.0% |
| Q4 FY2018 | Dec 31, 2018 | $1.76M | -49.0% |
| Q3 FY2018 | Sep 30, 2018 | $941.00K | -76.0% |
| Q2 FY2018 | Jun 30, 2018 | $2.76M | -27.8% |
| Q1 FY2018 | Mar 31, 2018 | $4.07M | +165.2% |
| Q4 FY2017 | Dec 31, 2017 | $3.46M | +84.4% |
| Q3 FY2017 | Sep 30, 2017 | $3.92M | +76.8% |
| Q2 FY2017 | Jun 30, 2017 | $3.83M | – |
| Q1 FY2017 | Mar 31, 2017 | $1.53M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.87M | – |
| Q3 FY2016 | Sep 30, 2016 | $2.22M | – |
See a number that looks wrong?